PSA, prostate-specific antigen; HALP, hemoglobin-albumin-lymphocyte-platelet; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; IQR, interquartile range; BPH, benign prostatic hyperplasia; IPC, incidental prostate cancer. This evidence concerns the gene NAT10 and benign prostatic hyperplasia.